Resource detail
CAR T 细胞疗法：用工程免疫细胞对抗癌症
Related articles
Share this on
References
1. Miliotou, A. N.; Papadopoulou, L. C., CAR-T-cell therapy: a new era in cancer immunotherapy. Current pharmaceutical biotechnology 2018, 19 (1), 5-18.
2. Sterner, R. C.; Sterner, R. M., CAR-T cell therapy: Current limitations and potential strategies. Blood cancer journal 2021, 11 (4), 1-11.
3. Srivastava, S.; Riddell, S. R., Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. The Journal of Immunology 2018, 200 (2), 459-468.
4. CAR-T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells.
5. Chimeric antigen receptor T cell. https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell.
6. Britannica, T. E. o. E., Chimera. https://www.britannica.com/topic/Chimera-Greek-mythology.
7. Chimeric Antigen Receptor (CAR) T-Cell Therapy: What Does “Chimeric” Mean? https://blog.dana-farber.org/insight/2018/01/chimeric-antigen-receptor-car-t-cell-therapy-chimeric-mean/.
8. The innate and adaptive immune ystems. https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=6219988d7a0dc92703826810.
9. Cano, R. L. E.; Lopera, H. D. E., Introduction to T and B lymphocytes. In Autoimmunity: From Bench to Bedside [Internet], El Rosario University Press: 2013.
10. Gonzalez, H.; Hagerling, C.; Werb, Z., Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes & development 2018, 32 (19-20), 1267-1284.
11. Torgovnick, A.; Schumacher, B., DNA repair mechanisms in cancer development and therapy. Frontiers in genetics 2015, 6, 157.
12. Portell, C. A., How Does CAR-T-Cell Therapy Work in Treating Cancer? https://www.cancer.net/blog/2021-06/how-does-car-t-cell-therapy-work-treating-cancer.
13. Ahmad, G.; Amiji, M. M., Cellular therapeutics in immuno-oncology. In Cancer Immunology and Immunotherapy, Elsevier: 2022; pp 237-265.
14. Chang, Z. L.; Chen, Y. Y., CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends in molecular medicine 2017, 23 (5), 430-450.
15. Ochi, T.; Maruta, M.; Tanimoto, K.; Kondo, F.; Yamamoto, T.; Kurata, M.; Fujiwara, H.; Masumoto, J.; Takenaka, K.; Yasukawa, M., A single-chain antibody generation system yielding CAR-T cells with superior antitumor function. Communications biology 2021, 4 (1), 1-13.
16. Dotti, G.; Gottschalk, S.; Savoldo, B.; Brenner, M. K., Design and development of therapies using chimeric antigen receptor‐expressing T cells. Immunological reviews 2014, 257 (1), 107-126.
17. Mougiakakos, D.; Krönke, G.; Völkl, S.; Kretschmann, S.; Aigner, M.; Kharboutli, S.; Böltz, S.; Manger, B.; Mackensen, A.; Schett, G., CD19-targeted CAR-T cells in refractory systemic lupus erythematosus. The New England journal of medicine 2021, 385 (6), 567-569.
18. Sommermeyer, D.; Hudecek, M.; Kosasih, P. L.; Gogishvili, T.; Maloney, D. G.; Turtle, C. J.; Riddell, S. R., Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 2016, 30 (2), 492-500.
19. Zhang, H.; Zhao, P.; Huang, H., Engineering better chimeric antigen receptor T cells. Experimental Hematology & Oncology 2020, 9 (1), 1-13.
20. Considerations for Appropriate Patient Selection. https://www.cartcellscience.com/car-t-cell-patient-selection/.
21. CAR-T-cell Therapy and Its Side Effects. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html.
22. Murad, J. P.; Kozlowska, A. K.; Lee, H. J.; Ramamurthy, M.; Chang, W.-C.; Yazaki, P.; Colcher, D.; Shively, J.; Cristea, M.; Forman, S. J., Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Frontiers in immunology 2018, 2268.
23. Zuo, S.; Wen, Y.; Panha, H.; Dai, G.; Wang, L.; Ren, X.; Fu, K., Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers. Molecular immunology 2017, 85, 293-304.
24. Zhou, R.; Yazdanifar, M.; Roy, L. D.; Whilding, L. M.; Gavrill, A.; Maher, J.; Mukherjee, P., CAR-T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Frontiers in immunology 2019, 10, 1149.
25. Han, Y.; Xie, W.; Song, D.-G.; Powell, D. J., Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR-T cells. Journal of Hematology & Oncology 2018, 11 (1), 1-13.
26. Weimin, S.; Abula, A.; Qianghong, D.; Wenguang, W., Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biology & Therapy 2020, 21 (6), 570-580.
27. Bui, M. H.; Seligson, D.; Han, K.-r.; Pantuck, A. J.; Dorey, F. J.; Huang, Y.; Horvath, S.; Leibovich, B. C.; Chopra, S.; Liao, S.-Y., Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clinical cancer research 2003, 9 (2), 802-811.
28. Zhao, W.; Jia, L.; Zhang, M.; Huang, X.; Qian, P.; Tang, Q.; Zhu, J.; Feng, Z., The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer. American journal of cancer research 2019, 9 (8), 1846.
29. Zhang, Z.; Jiang, J.; Wu, X.; Zhang, M.; Luo, D.; Zhang, R.; Li, S.; He, Y.; Bian, H.; Chen, Z., Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Frontiers of Medicine 2019, 13 (1), 57-68.
30. Katz, S. C.; Hardaway, J.; Prince, E.; Guha, P.; Cunetta, M.; Moody, A.; Wang, L. J.; Armenio, V.; Espat, N. J.; Junghans, R. P., HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Therapy 2020, 27 (5), 341-355.
31. Hombach, A. A.; Geumann, U.; Günther, C.; Hermann, F. G.; Abken, H., IL7-IL12 Engineered mesenchymal stem cells (MSCs) improve a CAR-T cell attack against colorectal cancer cells. Cells 2020, 9 (4), 873.
32. Marofi, F.; Motavalli, R.; Safonov, V. A.; Thangavelu, L.; Yumashev, A. V.; Alexander, M.; Shomali, N.; Chartrand, M. S.; Pathak, Y.; Jarahian, M., CAR-T cells in solid tumors: challenges and opportunities. Stem cell research & therapy 2021, 12 (1), 1-16.
33. Kuwana, Y.; Asakura, Y.; Utsunomiya, N.; Nakanishi, M.; Arata, Y.; Itoh, S.; Nagase, F.; Kurosawa, Y., Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions. Biochemical and biophysical research communications 1987, 149 (3), 960-968.
34. Gross, G.; Gorochov, G.; Waks, T.; Eshhar, Z. In Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity, Transplantation proceedings, 1989; pp 127-130.
35. T-cell receptor. https://en.wikipedia.org/wiki/T-cell_receptor.
36. Irving, B. A.; Weiss, A., The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991, 64 (5), 891-901.
37. Braendstrup, P.; Levine, B. L.; Ruella, M., The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy 2020, 22 (2), 57-69.
38. Sadelain, M.; Rivière, I.; Brentjens, R., Targeting tumours with genetically enhanced T lymphocytes. Nature Reviews Cancer 2003, 3 (1), 35-45.
39. Kochenderfer, J. N.; Rosenberg, S. A., Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nature reviews Clinical oncology 2013, 10 (5), 267-276.
40. Porter, D. L.; Levine, B. L.; Kalos, M.; Bagg, A.; June, C. H., Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N engl j Med 2011, 365, 725-733.
41. Kalos, M.; Levine, B. L.; Porter, D. L.; Katz, S.; Grupp, S. A.; Bagg, A.; June, C. H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational medicine 2011, 3 (95), 95ra73-95ra73.
42. Porter, D. L.; Hwang, W.-T.; Frey, N. V.; Lacey, S. F.; Shaw, P. A.; Loren, A. W.; Bagg, A.; Marcucci, K. T.; Shen, A.; Gonzalez, V., Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science translational medicine 2015, 7 (303), 303ra139-303ra139.
43. Maude, S. L.; Frey, N.; Shaw, P. A.; Aplenc, R.; Barrett, D. M.; Bunin, N. J.; Chew, A.; Gonzalez, V. E.; Zheng, Z.; Lacey, S. F., Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine 2014, 371 (16), 1507-1517.
44. Maude, S. L.; Pulsipher, M. A.; Boyer, M. W.; Grupp, S. A.; Davies, S. M.; Phillips, C. L.; Verneris, M. R.; August, K. J.; Schlis, K.; Driscoll, T. A., Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood 2016, 128 (22), 2801.
45. Maude, S. L.; Laetsch, T. W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M. R.; Stefanski, H. E.; Myers, G. D., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine 2018, 378 (5), 439-448.
46. Schuster, S. J.; Svoboda, J.; Chong, E. A.; Nasta, S. D.; Mato, A. R.; Anak, Ö.; Brogdon, J. L.; Pruteanu-Malinici, I.; Bhoj, V.; Landsburg, D., Chimeric antigen receptor T cells in refractory B-cell lymphomas. New England Journal of Medicine 2017, 377 (26), 2545-2554.
47. Schuster, S. J.; Bishop, M. R.; Tam, C. S.; Waller, E. K.; Borchmann, P.; McGuirk, J. P.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J. R., Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine 2019, 380 (1), 45-56.
48. Hu, Y.; Huang, J., The chimeric antigen receptor detection toolkit. Frontiers in Immunology 2020, 1770.
49. Davenport, A.; Cross, R.; Watson, K.; Liao, Y.; Shi, W.; Prince, H.; Beavis, P.; Trapani, J.; Kershaw, M.; Ritchie, D., Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proceedings of the National Academy of Sciences 2018, 115 (9), E2068-E2076.
50. Long, A. H.; Haso, W. M.; Shern, J. F.; Wanhainen, K. M.; Murgai, M.; Ingaramo, M.; Smith, J. P.; Walker, A. J.; Kohler, M. E.; Venkateshwara, V. R., 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature medicine 2015, 21 (6), 581-590.
51. Xiong, W.; Chen, Y.; Kang, X.; Chen, Z.; Zheng, P.; Hsu, Y.-H.; Jang, J. H.; Qin, L.; Liu, H.; Dotti, G., Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Molecular Therapy 2018, 26 (4), 963-975.
52. Su, X.; Vale, R., Mechanisms of chimeric antigen receptor (CAR) signaling during T cell activation. Biophysical Journal 2018, 114 (3), 107a-108a.
53. Jiaming Zhang, B. J. L., Grace Yang, Peifang Ye, Nancy Li, Yama Abass, Real-Time Potency Assay for CAR-T-Cell Killing of Cancer Cells. https://www.genengnews.com/resources/tutorial/real-time-potency-assay-for-car-t-cell-killing-of-cancer-cells/.
54. Close, D. M.; Xu, T.; Sayler, G. S.; Ripp, S., In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals. Sensors 2011, 11 (1), 180-206.
55. CYTOSMART Product overview. https://cytosmart.com/product-overview.
56. Torres Chavez, A.; McKenna, M. K.; Canestrari, E.; Dann, C. T.; Ramos, C. A.; Lulla, P.; Leen, A. M.; Vera, J. F.; Watanabe, N., Expanding CAR-T cells in human platelet lysate renders T cells with in vivo longevity. Journal for immunotherapy of cancer 2019, 7 (1), 1-15.
57. Dawson, N. A.; Lamarche, C.; Hoeppli, R. E.; Bergqvist, P.; Fung, V. C.; McIver, E.; Huang, Q.; Gillies, J.; Speck, M.; Orban, P. C., Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells. JCI insight 2019, 4 (6).
58. Serganova, I.; Moroz, E.; Cohen, I.; Moroz, M.; Mane, M.; Zurita, J.; Shenker, L.; Ponomarev, V.; Blasberg, R., Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1/PD-L1 blockade. Molecular Therapy-Oncolytics 2017, 4, 41-54.
59. Stowe, C. L.; Burley, T. A.; Allan, H.; Vinci, M.; Kramer-Marek, G.; Ciobota, D. M.; Parkinson, G. N.; Southworth, T. L.; Agliardi, G.; Hotblack, A., Near-infrared dual bioluminescence imaging in mouse models of cancer using infraluciferin. Elife 2019, 8, e45801.
60. Mezzanotte, L.; van‘t Root, M.; Karatas, H.; Goun, E. A.; Löwik, C. W., In vivo molecular bioluminescence imaging: new tools and applications. Trends in biotechnology 2017, 35 (7), 640-652.
61. Sadikot, R. T.; Blackwell, T. S., Bioluminescence imaging. Proceedings of the American Thoracic Society 2005, 2 (6), 537-540.
62. Ishii, T.; Ishii, M., Intravital two-photon imaging: a versatile tool for dissecting the immune system. Annals of the Rheumatic Diseases 2011, 70 (Suppl 1), i113-i115.
63. Cazaux, M.; Grandjean, C. L.; Lemaître, F.; Garcia, Z.; Beck, R. J.; Milo, I.; Postat, J.; Beltman, J. B.; Cheadle, E. J.; Bousso, P., Single-cell imaging of CAR-T cell activity in vivo reveals extensive functional and anatomical heterogeneity. Journal of Experimental Medicine 2019, 216 (5), 1038-1049.
64. Mulazzani, M.; Fräßle, S. P.; von Mücke-Heim, I.; Langer, S.; Zhou, X.; Ishikawa-Ankerhold, H.; Leube, J.; Zhang, W.; Dötsch, S.; Svec, M., Long-term in vivo microscopy of CAR-T cell dynamics during eradication of CNS lymphoma in mice. Proceedings of the National Academy of Sciences 2019, 116 (48), 24275-24284.
65. Ma, B.; Liu, F.; Zhang, S.; Duan, J.; Kong, Y.; Li, Z.; Tang, D.; Wang, W.; Ge, S.; Tang, W., Two-photon fluorescent polydopamine nanodots for CAR-T cell function verification and tumor cell/tissue detection. Journal of Materials Chemistry B 2018, 6 (40), 6459-6467.
66. Alavi, A.; Huang, S. S., Positron emission tomography in medicine: an overview. Cancer Imaging 2008, 39-44.
67. Weist, M. R.; Starr, R.; Aguilar, B.; Chea, J.; Miles, J. K.; Poku, E.; Gerdts, E.; Yang, X.; Priceman, S. J.; Forman, S. J., PET of adoptively transferred chimeric antigen receptor T cells with 89Zr-oxine. Journal of Nuclear Medicine 2018, 59 (10), 1531-1537.
68. Parente-Pereira, A. C.; Burnet, J.; Ellison, D.; Foster, J.; Davies, D. M.; Van der Stegen, S.; Burbridge, S.; Chiapero-Stanke, L.; Wilkie, S.; Mather, S., Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. Journal of clinical immunology 2011, 31 (4), 710-718.
69. Volpe, A.; Lang, C.; Lim, L.; Man, F.; Kurtys, E.; Ashmore-Harris, C.; Johnson, P.; Skourti, E.; de Rosales, R. T.; Fruhwirth, G. O., Spatiotemporal PET imaging reveals differences in CAR-T tumor retention in triple-negative breast cancer models. Molecular Therapy 2020, 28 (10), 2271-2285.
70. Kiraga, Ł.; Kucharzewska, P.; Paisey, S.; Cheda, Ł.; Domańska, A.; Rogulski, Z.; Rygiel, T. P.; Boffi, A.; Król, M., Nuclear imaging for immune cell tracking in vivo–Comparison of various cell labeling methods and their application. Coordination chemistry reviews 2021, 445, 214008.
71. Krebs, S.; Ahad, A.; Carter, L. M.; Eyquem, J.; Brand, C.; Bell, M.; Ponomarev, V.; Reiner, T.; Meares, C. F.; Gottschalk, S., Antibody with infinite affinity for in vivo tracking of genetically engineered lymphocytes. Journal of Nuclear Medicine 2018, 59 (12), 1894-1900.
72. Park, S.; Shevlin, E.; Vedvyas, Y.; Zaman, M.; Park, S.; Hsu, Y.-M. S.; Min, I. M.; Jin, M. M., Micromolar affinity CAR-T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Scientific reports 2017, 7 (1), 1-15.
73. Bhanat, E.; Koch, C. A.; Parmar, R.; Garla, V.; Vijayakumar, V., Somatostatin receptor expression in non-classical locations–clinical relevance? Reviews in Endocrine and Metabolic Disorders 2018, 19 (2), 123-132.
74. Sellmyer, M. A.; Richman, S. A.; Lohith, K.; Hou, C.; Weng, C.-C.; Mach, R. H.; O’Connor, R. S.; Milone, M. C.; Farwell, M. D., Imaging CAR-T cell trafficking with eDHFR as a PET reporter gene. Molecular Therapy 2020, 28 (1), 42-51.
75. Shah, N. N.; Nagle, S. J.; Torigian, D. A.; Farwell, M. D.; Hwang, W.-T.; Frey, N.; Nasta, S. D.; Landsburg, D.; Mato, A.; June, C. H., Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor–T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy 2018, 20 (12), 1415-1418.
76. Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2. https://clinicaltrials.gov/ct2/show/NCT01082926
ClinicalTrials.gov Identifier: NCT01082926.
77. Keu, K. V.; Witney, T. H.; Yaghoubi, S.; Rosenberg, J.; Kurien, A.; Magnusson, R.; Williams, J.; Habte, F.; Wagner, J. R.; Forman, S., Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science translational medicine 2017, 9 (373), eaag2196.
78. Möhn, N.; Bonda, V.; Grote-Levi, L.; Panagiota, V.; Fröhlich, T.; Schultze-Florey, C.; Wattjes, M. P.; Beutel, G.; Eder, M.; David, S., Neurological management and work-up of neurotoxicity associated with CAR-T cell therapy. Neurological Research and Practice 2022, 4 (1), 1-10.
79. Kiru, L.; Zlitni, A.; Tousley, A. M.; Dalton, G. N.; Wu, W.; Lafortune, F.; Liu, A.; Cunanan, K. M.; Nejadnik, H.; Sulchek, T., In vivo imaging of nanoparticle-labeled CAR-T cells. Proceedings of the National Academy of Sciences 2022, 119 (6).
80. Dubois, V. P.; Sehl, O. C.; Foster, P. J.; Ronald, J. A., Visualizing CAR-T cell Immunotherapy Using 3 Tesla Fluorine-19 MRI. Molecular Imaging and Biology 2021, 1-11.
81. Lee, S. H.; Soh, H.; Chung, J. H.; Cho, E. H.; Lee, S. J.; Ju, J.-M.; Sheen, J. H.; Kim, H.; Oh, S. J.; Lee, S.-J., Feasibility of real-time in vivo 89Zr-DFO-labeled CAR-T-cell trafficking using PET imaging. PLoS One 2020, 15 (1), e0223814.
82. Bachanova, V.; Bishop, M. R.; Dahi, P.; Dholaria, B.; Grupp, S. A.; Hayes-Lattin, B.; Janakiram, M.; Maziarz, R. T.; McGuirk, J. P.; Nastoupil, L. J., Chimeric antigen receptor T cell therapy during the COVID-19 pandemic. Biology of Blood and Marrow Transplantation 2020, 26 (7), 1239-1246.
Want to stay up to date? Sign up for our newsletter
No, thanks